Project description:Transcriptional profiling of Mycobacterium tuberculosis mc2 7000 surviving 4 days of isoniazid treatment relative to untreated to investigate genes relevant to survival in genotypically isoniazid-sensitive cells
Project description:The ability of Mycobacterium tuberculosis (Mtb) to adopt heterogeneous physiological states, underlies it’s success in evading the immune system and tolerating antibiotic killing. Drug tolerant phenotypes are a major reason why the tuberculosis (TB) mortality rate is so high, with over 1.8 million deaths annually. To develop new TB therapeutics that better treat the infection (faster and more completely), a systems-level approach is needed to reveal the complexity of network-based adaptations of Mtb. Here, we report the transcriptional response of Mtb to the drug isoniazid. We performed transcriptomic sequencing (RNA-seq) on Mtb bacilli at 4, 24, 72 h following exposure to the drug.
Project description:Transcriptional profiling of Mycobacterium tuberculosis H37Rv after 4 hours of combination isoniazid and cysteine treatment relative to treatment with isoniazid alone.
Project description:We identified mce3R and ctpD as genes that could alter M tuberculosis (Mtb) response to isoniazid when perturbed using a regulatory network-based TRIP screen [see associated data at PRJNA483505]. To investigate the mechanisms underlying this response, we performed RNAseq on genetically perturbed mutant strains either in the presence or absence of isoniazid.
Project description:Bacteria commonly adapt to stresses by altering gene expression. To understand the response of M. tuberculosis (MTB) to various antibacterial agents, we performed transcriptomics on MTB bacilli exposed to several test compounds as well as known drugs (capreomycin, cycloserine, ethionamide, isoniazid, kanamycin, moxifloxacin, PA-824, rifampicin, streptomycin).